<DOC>
	<DOCNO>NCT02253212</DOCNO>
	<brief_summary>PURPOSE : The purpose study determine whether transient open blood-brain barrier pulse ultrasound use SonoCloud implantable ultrasound device safely tolerate patient recurrent glioblastoma immediately systemic delivery carboplatin-based chemotherapy . STUDY HYPOTHESIS : The blood-brain barrier safely open use pulse ultrasound prior chemotherapy administration patient recurrent glioblastoma . Transient open blood-brain barrier pulse ultrasound increase glioblastoma exposure carboplatin-based chemotherapy increase progression-free overall survival patient recurrent glioblastoma .</brief_summary>
	<brief_title>Safety BBB Opening With SonoCloud</brief_title>
	<detailed_description>For patient recurrent malignant glioma , already treat combination surgery , radiation therapy and/or chemotherapy , treatment option currently exist . Salvage therapy typically consist systemic administration chemotherapy agent , show limited effectiveness median survival patient group currently 6 month . One limitation efficacy systemic chemotherapy treatment brain tumor blood-brain barrier ( BBB ) . To enhance delivery systemically administer chemotherapy agent brain tumor , implantable ultrasound device develop use temporarily disrupt BBB . Delivery pulse ultrasound , combination ultrasound contrast agent , show temporarily disrupt BBB duration 6 hour allow significantly increase penetration systemically administer chemotherapy drug pre-clinical study . This study evaluate safety temporary disruption BBB carboplatin chemotherapy delivery patient recurrent glioblastoma . This study also evaluate maximum tolerate dose ultrasound use disrupt BBB . The use dynamic contrast-enhanced MRI evaluate determine extent magnitude BBB opening . Clinical efficacy ( Survival ) radiological efficacy ( Progression Free Survival ) also evaluate secondary endpoint .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : Age great 18 year . Subjects recurrent glioma fail standard therapy surgery and/or treatment radiation temozolomide . Patient eligible Carboplatinbased chemotherapy Contrastenhanced tumor le 35 mm diameter No risk cerebral herniation Able tolerate pre/post procedure steroid treatment Social security affiliate ( France ) Able willing give sign informed consent Normal biological status Hemoglobin ≥ 10 g/dl Platelets ≥ 100000/mm3 Neutrophils ≥ 1500/mm3 Normal creatine clearance ≥ 60ml/mn ASAT &lt; 3 N ALAT &lt; 3 N Normal Bilirubin Level &lt; 1.5 N Alkaline Phosphatase &lt; 3 N INR &lt; 1.5 Prothrombin Level ≥ 70 % Exclusion criterion : Allergic Iodine , Gadolinium , Xylocain Contraindications echographic contrast agent ( microbubbles ) Severe Renal insufficiency Hepatic insufficiency Possible toxic treatment CNS Previously infect surgical field Uncontrolled epilepsy MRI contraindication Hemostasis trouble thrombopenia &lt; 75.000 , TP &lt; 60 % , INR &gt; 1.5 , antiplatelet anticoagulant therapy ongoing ) Active phlebitis active pulmonary embolism Pregnant currently breastfeed Patients judicial protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>